The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
Open accessAbstract
Human papillomavirus (HPV) infection, usually a sexually transmitted disease, is a risk factor for cervical cancer. Given the substantial disease and death associated with HPV and cervical cancer, development of a prophylactic HPV vaccine is a public health priority. We evaluated the cost-effectiveness of vaccinating adolescent girls for high-risk HPV infections relative to current practice. A vaccine with a 75% probability of immunity against high-risk HPV infection resulted in a life-expectancy gain of 2.8 days or 4.0 quality-adjusted life days at a cost of $246 relative to current practice (incremental cost effectiveness of $22,755/quality-adjusted life year [QALY]). If all 12-year-old girls currently living in the United States were vaccinated, >1,300 deaths from cervical cancer would be averted during their lifetimes. Vaccination of girls against high-risk HPV is relatively cost effective even when vaccine efficacy is low. If the vaccine efficacy rate is 35%, the cost effectiveness increases to $52,398/QALY. Although gains in life expectancy may be modest at the individual level, population benefits are substantial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., Shan, K. V., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.11.796 · Cited by 3,370
Natural History of Cervicovaginal Papillomavirus Infection in Young Women
Ho, G. Y. F., Bierman, R., Beardsley, L., Chang, C. J., & Burk, R. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380703 · Cited by 2,329
Report of the Committee on Infectious Diseases
Nider, H. (1989) · Archives of Dermatology · doi:10.1001/archderm.1989.01670190156031 · Cited by 1,911
NATURAL HISTORY OF CERVICOVAGINAL PAPILLOMAVIRUS INFECTION IN YOUNG WOMEN
Loria, G. R., Ierman, R. O. B., Eardsley, L. E. B., & Hang, H. J. C. (1998) · Cited by 1,890
NATURAL HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA
RICHART, R. M. (1967) · Clinical Obstetrics and Gynecology · doi:10.1097/00003081-196712000-00002 · Cited by 1,376
Natural History of Cervical Intraepithelial Neoplasia: A Critical Review
Östör, A. G. (1993) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199304000-00018 · Cited by 1,260
Schiffman, M. H., Bauer, H. M., Hoover, R. N., Glass, A. G., Cadell, D. M., Rush, B. B., Scott, D. R., Sherman, M. E., Kurman, R. J., Wacholder, S., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.12.958 · Cited by 1,210
Solomon, D., Schiffman, M., & Tarone, R. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.293 · Cited by 975
Eddy, D. M. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-3-214 · Cited by 837
Cited by
Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007) · PsycEXTRA Dataset · doi:10.1037/e601292007-001 · Cited by 1,882
Rahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D'Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 738
Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., & Franco, E. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh104 · Cited by 539
Saslow, D., Castle, P. E., Cox, J. T., Davey, D. D., Einstein, M. H., Ferris, D. G., Goldie, S. J., Harper, D. M., Kinney, W., Moscicki, A.-B., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.7 · Cited by 521
Model for Assessing Human Papillomavirus Vaccination Strategies
Elbasha, E. H., Dasbach, E. J., & Insinga, R. P. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1301.060438 · Cited by 491
Block, S. L., Nolan, T., Sattler, C., Barr, E., Giacoletti, K. E. D., Marchant, C. D., Castellsagué, X., Rusche, S. A., Lukac, S., Bryan, J. T., et al. (2006) · Pediatrics · doi:10.1542/peds.2006-0461 · Cited by 484
Evaluating Human Papillomavirus Vaccination Programs
Taira, A. V., Neukermans, C. P., & Sanders, G. D. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1011.040222 · Cited by 379
Self-citationHealth and Economic Implications of HPV Vaccination in the United States
Kim, J. J., & Goldie, S. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa0707052 · Cited by 365
Quadrivalent Human Papillomavirus Vaccine
Gellin, B., Modlin, J. F., Barr, E., & Tamms, G. (2007) · Clinical Infectious Diseases · doi:10.1086/520654 · Cited by 330
Barnabas, R. V., Laukkanen, P., Koskela, P., Kontula, O., Lehtinen, M., & Garnett, G. P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030138 · Cited by 293
Welte, R., Feenstra, T., Jager, H., & Leidl, R. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422130-00004 · Cited by 292
Goldhaber-Fiebert, J. D., Stout, N. K., Salomon, J. A., Kuntz, K. M., & Goldie, S. J. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn019 · Cited by 286
Griebsch, I., Coast, J., & Brown, J. (2005) · Pediatrics · doi:10.1542/peds.2004-2127 · Cited by 270
Goldie, S. J., Grima, D., Kohli, M., Wright, T. C., Weinstein, M., & Franco, E. (2003) · International Journal of Cancer · doi:10.1002/ijc.11334 · Cited by 209
Sensitivity analysis methods in the biomedical sciences
Qian, G., & Mahdi, A. (2020) · Mathematical Biosciences · doi:10.1016/j.mbs.2020.108306 · Cited by 169
Van de Velde, N., Brisson, M., & Boily, M.-C. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.05.056 · Cited by 87
Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand
Praditsitthikorn, N., Teerawattananon, Y., Tantivess, S., Limwattananon, S., Riewpaiboon, A., Chichareon, S., Ieumwananonthachai, N., & Tangcharoensathien, V. (2011) · PharmacoEconomics · doi:10.2165/11586560-000000000-00000 · Cited by 79
The predicted impact of vaccination on human papillomavirus infections in Australia
Smith, M. A., Canfell, K., Brotherton, J. M. L., Lew, J., & Barnabas, R. V. (2008) · International Journal of Cancer · doi:10.1002/ijc.23633 · Cited by 54
Metadata
- Authors
- Sanders, G. D., & Taira, A. V.
- Venue
- Emerging Infectious Diseases
- Published
- 2003-01
- Volume
- 9
- Issue
- 1
- Pages
- 37-48
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W1969228545
- Cited by
- 310
- References
- 69
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.